Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 26 Issue 6, June 2020

Volume 26 Issue 6

Diagnosis of skin diseases with AI

The cover illustration showcases the concept and functionality of the machine-learning model developed by Liu et al. to identify and assist in the diagnosis of skin conditions in routine clinical practice through everyday technology such as cellphones and laptops. By leveraging these devices, this research potentially expands universal access to high-quality information about skin conditions and may accelerate the deployment of digital solutions into clinical practice.

See Liu et al.

Image credit: Carson Young. Cover design: Erin Dewalt

Editorial

  • Editorial |

    Government officials who disseminate unsupported claims about the novel coronavirus undermine public trust in science and in the public-health efforts that are essential to bringing the COVID-19 pandemic under control.

Turning Points

  • Turning Points |

    Francesco Paolo Russo, an Associate Professor of Gastroenterology at the Department of Surgery, Oncology and Gastroenterology of the University Hospital in Padua, Italy, talks about carrying out research, teaching and clinical work in the midst of the COVID-19 pandemic.

    • Francesco Paolo Russo

Correspondence

World View

Comment

  • Comment |

    Necessity has been the mother of invention in the response to the COVID-19 pandemic, triggering many an innovation, often without the luxury of time to test these makeshift solutions to pressing problems. But there is much to be learned from times of crisis for times of plenty.

    • Matthew Harris
    • Yasser Bhatti
    • Dhananjaya Sharma
  • Comment |

    Researchers starting clinical trials of prevention measures for COVID-19 have a unique window of opportunity for collecting blood from the participants, at baseline and at the end of the trial, to be able to incorporate critical data into their analysis once serological tests for the causative coronavirus become available.

    • Marc Lipsitch
    • Rebecca Kahn
    • Michael J. Mina
  • Comment |

    In the USA and around the world, the COVID-19 pandemic arrived as the population was fighting a devastating opioid overdose epidemic. Urgent and decisive action is needed to protect particularly vulnerable populations, such as those with opioid use disorder, to prevent a compounding effect on public health.

    • Sarah E. Wakeman
    • Traci C. Green
    • Josiah Rich
  • Comment |

    Testing drug safety in people who are pregnant remains a wicked problem, but in the transition toward big data and machine learning, target trials could afford a viable alternative to randomized, controlled trials.

    • Anup P. Challa
    • Robert R. Lavieri
    • David M. Aronoff

Research Highlights

News & Views

Perspectives

Brief Communications

  • Brief Communication |

    Single-cell transcriptome and T cell receptor analysis of bronchoalveolar lavage fluid suggests enrichment of proinflammatory macrophages in patients with severe COVID-19 and the presence of clonally expanded CD8+ T cells in patients with moderate COVID-19.

    • Mingfeng Liao
    • Yang Liu
    • Zheng Zhang
  • Brief Communication |

    A cross-sectional study of hospitalized patients with COVID-19 and a longitudinal follow-up study of patients with COVID-19 suggest that SARS-CoV2-specific IgG or IgM seroconversion occurs within 20 days post symptom onset.

    • Quan-Xin Long
    • Bai-Zhong Liu
    • Ai-Long Huang

Letters

Articles

Analysis

Amendments & Corrections

Search

Quick links